STOCK TITAN
  1. Home
  2. Sec-filings
  3. BRTX
  4. [8-K] BioRestorative Therapies, Inc. Reports Material Event

Nasdaq puts BioRestorative (NASDAQ: BRTX) on the clock over missing 10‑Q

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

BioRestorative Therapies, Inc. (BRTX) reports receiving a delinquency notification letter from Nasdaq on August 21, 2026 because it did not timely file its Form 10‑Q for the quarter ended June 30, 2026, putting it out of compliance with Nasdaq Listing Rule 5250(c)(1). The company’s common stock continues to trade on the Nasdaq Capital Market under the symbol BRTX, and the notice has no immediate effect on the listing. BioRestorative Therapies has until October 20, 2026 to submit a plan to regain compliance; if Nasdaq accepts the plan, it may grant an exception of up to 180 days from the Form 10‑Q due date, through February 16, 2027. If Nasdaq does not accept the plan, the company may appeal to a Nasdaq Hearings Panel. The company states it is working to complete and file the Form 10‑Q and to submit a compliance plan.

Positive

  • None.

Negative

  • Nasdaq noncompliance and delisting risk: The company is out of compliance with Nasdaq Listing Rule 5250(c)(1) due to its late Form 10‑Q for the quarter ended June 30, 2026, and faces potential delisting if it cannot regain compliance by up to February 16, 2027 or through any appeal.

Filing Explained

BRTX common stock remains listed for now, but the filing identifies possible delisting if the company does not regain Nasdaq compliance within the prescribed period or any granted extension; continued trading does not resolve the listing issue.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Notice date August 21, 2026 Date Nasdaq issued the delinquency notification letter to the company
Form 10-Q period end June 30, 2026 Quarterly period for the Form 10‑Q that was not filed on time
Compliance plan deadline October 20, 2026 Deadline to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1)
Maximum exception period end February 16, 2027 Latest date through which Nasdaq may grant an exception, up to 180 days from the Form 10‑Q due date
Nasdaq Listing Rule 5250(c)(1) Rule requiring timely filing of all required periodic financial reports
delinquency notification letter regulatory
"received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department"
A delinquency notification letter is a formal notice sent by a lender or servicer to a borrower informing them that a scheduled payment has been missed and outlining next steps, fees, or deadlines to cure the delinquency. For investors, these letters signal higher credit risk in a loan portfolio—like a red flag on a borrower’s payment behavior—and can foreshadow reduced cash flow, higher collection costs, or eventual default that affect returns.
Nasdaq Listing Rule 5250(c)(1) regulatory
"not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies"
Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.
Nasdaq Hearings Panel regulatory
"the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
continued listing requirements regulatory
"ability to regain and maintain compliance with Nasdaq’s continued listing requirements"
Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.

FAQ

Why did BioRestorative Therapies (BRTX) receive a Nasdaq delinquency notice?
BioRestorative Therapies received a delinquency notification letter from Nasdaq on August 21, 2026 because it did not timely file its Form 10‑Q for the quarter ended June 30, 2026, putting it out of compliance with Nasdaq Listing Rule 5250(c)(1).

Is BioRestorative Therapies (BRTX) still listed on Nasdaq after this notice?
Yes. The company states the notice has no immediate effect on the listing, and its common stock continues to trade on the Nasdaq Capital Market under the symbol BRTX while it works to regain compliance.

What deadline does BRTX have to submit a compliance plan to Nasdaq?
BioRestorative Therapies has until October 20, 2026 to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1). If Nasdaq accepts the plan, it may grant additional time for the company to file the delayed Form 10‑Q.

How long an extension might Nasdaq grant BioRestorative Therapies (BRTX)?
If Nasdaq accepts the company’s plan, it may grant an exception of up to 180 calendar days from the Form 10‑Q due date, or until February 16, 2027, for BioRestorative Therapies to regain compliance with its periodic reporting obligations.

What happens if Nasdaq rejects BRTX’s compliance plan?
If Nasdaq does not accept the company’s compliance plan, BioRestorative Therapies will have the opportunity to appeal the decision to a Nasdaq Hearings Panel. The company also notes that its stock could be delisted if it fails to regain compliance within the allowed period.

What actions is BioRestorative Therapies (BRTX) taking in response to the notice?
The company states it is working prudently to complete and file the delayed Form 10‑Q for the quarter ended June 30, 2026 and to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) by the October 20, 2026 deadline.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001505497 0001505497 2026-08-21 2026-08-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 8-K

  

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 21, 2026

  

BIORESTORATIVE THERAPIES, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-37603   30-1341024
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

40 Marcus Drive

Melville, New York

   11747
(Address of principal executive offices)   (Zip Code)

 

(631) 760-8100

(Registrant’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   BRTX   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On August 21, 2026, BioRestorative Therapies, Inc. (the “Company”) received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.

 

The Notice has no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol “BRTX”.

 

As indicated in the Notice, the Company has until October 20, 2026, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, it may grant an exception of up to 180 calendar days from the Form 10-Q’s due date, or until February 16, 2027, for the Company to regain compliance. If Nasdaq does not accept the Company’s compliance plan, the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel.

 

The Company is working prudently to complete and file the Form 10-Q and submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1).

 

Cautionary Note Regarding Forward-Looking Statements

 

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the Company’s ability to complete and file the Form 10-Q, the Company’s ability to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1), whether Nasdaq will accept such plan, the timing and outcome of any compliance period or extension that may be granted by Nasdaq, and the Company’s ability to regain and maintain compliance with Nasdaq’s continued listing requirements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with the Company’s ability to complete its financial statements and related disclosures in a timely manner, the availability of internal and external resources necessary to prepare and file the Form 10-Q, Nasdaq’s acceptance or rejection of the Company’s compliance plan, the possibility that the Company’s common stock could be delisted from Nasdaq if the Company fails to regain compliance within the period prescribed by Nasdaq or any extension granted, and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 1 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 25, 2026

 

  BIORESTORATIVE THERAPIES, INC.
   
  By: /s/ Katharyn Field
  Name: Katharyn Field
  Title: Director, Chief Executive Officer, President and Interim Chief Financial Officer 

 

 2 

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents